Monoclonal Antibodies Market (2025-2032)
The Monoclonal Antibodies Market is projected to reach $449.8 billion by 2032 at a CAGR of 11.2% from 2025 to 2032.
- Published
- Jun 2024
- Pages
- 410
- Format
- PDF + Excel
- Report ID
- MRHC - 1041246
- Base year
- 2024
- 2032 · FORECAST
- $449.8B
- 2032
- $449.8B
- CAGR 2025–2032
- 11.2%
2024 baseline · 2025–2032 forecast at 11.2% CAGR · hover a bar for the value
Key highlights
By Type: In 2025, the Therapeutic Monoclonal Antibodies Segment to Dominate the Monoclonal Antibodies Market
By Production Process: In 2025, the In Vitro Process Segment to Dominate the Monoclonal Antibodies Market
By Source: In 2025, the Human Segment to Dominate the Monoclonal Antibodies Market
By End User: In 2025, the Hospitals Segment to Dominate the Monoclonal Antibodies Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 410 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 11.2% |
| Estimated Market Size (Value) | $449.8 billion by 2032 |
| Segments Covered | By Type · Research Monoclonal Antibodies · Research Area · Oncology · Infectious Diseases · Cardiology · Immunology · Neurology · Stem Cell Research · Other Research Areas · Application · Proteomics · Drug Discovery and Development · Genomics · Technology · Flow Cytometry · Immunofluorescence · Enzyme-Linked Immunosorbent Assay · Multiplex Immunosorbent Assay · Western Blot · Immunohistochemistry · Immunoprecipitation (IP) · Other Research Technologies · Diagnostic Monoclonal Antibodies · Application · Oncology · Infectious Diseases · Pregnancy Detection/Fertility Testing · Cardiac Marker Testing · Other Diagnostic Applications · Technology · ELISA · Lateral Flow Assay · Immunohistochemistry (IHC) · Immunoprecipitation (IP) · Western Blot (WB) · Immunocytochemistry (ICC) · Other Diagnostic Technologies · Therapeutic Monoclonal Antibodies · Therapeutic Area · Oncology · Autoimmune Diseases · Neurological Diseases · Infectious Diseases · Other Therapeutic Areas · Route of Administration · Subcutaneous · Intravenous Cell Therapy · (Note 1: Other research areas include Ophthalmology and Rare Diseases) · (Note 2: Other research technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay) · (Note 3: Other diagnostic applications include Alzheimer’s, autoimmune diseases, cardiac diseases, and diabetes.) · (Note 4: Other diagnostic technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.) · (Note 5: Other therapeutic areas include cardiac diseases, diabetes, ophthalmology, and hematology.) · By Production Process · In Vivo Process · In Vitro Process · Upstream Process · Downstream Process · By Source · Human · Humanized · Chimeric · Murine · Other Sources · (Note: Other sources include goat, sheep, chicken, and llama) · By End User · Pharmaceutical & Biotechnology Companies · Hospitals · Contract Research Organizations · Other End Users · (Note: Other end users include Academic & research institutes, nursing centers, and long-term care centers) |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa |
| Key Companies | The key players operating in the global monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.) |
Report overview
Segments covered: type, source, production, end user. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics.
Furthermore, increasing R&D investments by pharmaceutical and biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities.
Report infographic
Market dynamics
5 factors across 3 forcesHigh Burden of Cancer and Autoimmune Diseases Globally
Cancer poses a major burden on the global population. For instance, the total number of new cancer cases is estimated to reach 24.6 million by 2032 from 19.3 million in 2020 (Source: International Agency for Research on Cancer). Monoclonal antibodies (mABs) are used for the treatment of cancer as mABs. These targeted drugs identify specific proteins and cancer cells and help in the inhibition of their growth.
Additionally, monoclonal antibodies are used to treat autoimmune diseases, a condition in which the body's immune system attacks its tissues, causing inflammation, damage to healthy tissues, and sometimes organ dysfunction. Several anti-inflammatory monoclonal antibodies are used in the treatment of autoimmune diseases. For instance, monoclonal antibodies used to treat arthritis are known as tumor necrosis factor (TNF) inhibitors. TNF is a protein involved in causing inflammation and damage of rheumatoid arthritis.
Growth in the Biopharmaceutical Industry
The market for biopharmaceuticals is increasing due to the increasing number of bio-approvals, companies’ rising emphasis on expanding biomanufacturing capacities, and government initiatives supporting bioproduction. In 2021, 5,500 new planned clinical trials have started, an increase of 14% from 2020 and 19% from 2019.
Government agencies worldwide are undertaking initiatives to support the growth of the biopharmaceutical market. For instance, the Chinese government has undertaken several initiatives for the development and commercialization of biosimilars. Countries like Malaysia, Indonesia, Thailand, and Taiwan have established regulatory pathways for biosimilars, increasing access to biosimilar technology. The growth in the biopharmaceutical industry is driving the development of monoclonal antibodies (mAbs). mAbs are regarded as one of the fastest-growing classes of biopharmaceuticals.
Table of contents
12 chapters · 159 sections · 410 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Type | Therapeutic Monoclonal Antibodies | — |
| By Production Process | In Vitro Process | — |
| By Source | Human | — |
| By End User | Hospitals | — |
By Type
- The therapeutic monoclonal antibodies segment is expected to account for the largest share of 90.2% of the monoclonal antibodies market.
- This segment’s large market share can be attributed to factors such as the wide range of applications of monoclonal antibodies in therapeutics for various diseases and conditions, the increasing prevalence of chronic diseases, and the growing focus of pharmaceutical and biopharmaceutical companies on the development of monoclonal antibody-based therapeutics.
- Furthermore, recent approvals for therapeutic monoclonal antibodies contribute to the growth of this segment.
- For instance, in August 2024, Regeneron Pharmaceuticals, Inc. (U.S.) received approval for Veopoz (pozelimab-bbfg) for the treatment of adult and pediatric patients one year of age and older with CHAPLE disease.
- Similarly, in August 2024, Pfizer Inc. (U.S.) received approval for ELREXFIO (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).
By Production Process
- The In Vitro Process Segment to Dominate the Monoclonal Antibodies Market
- The in vitro process segment is expected to account for the largest share of the monoclonal antibodies market.
- In vitro antibody production methods involve the use of recombinant technology, hybridoma cells, or mammalian cell culture to produce monoclonal antibodies.
- This segment's large market share can be attributed to benefits offered by in vitro production methods, including the production of specific antibody isotypes, the generation of antibodies with uniformity and high specificity, reduced reliance on mouse models through the use of humanized mouse models, and a reduced risk of immunogenicity.
By Source
- The Human Segment to Dominate the Monoclonal Antibodies Market
- The human segment is expected to account for the largest share of 33.2% of the monoclonal antibodies market.
- The increased utilization of human cell lines for monoclonal antibody production, which yields antibodies most similar to those naturally produced in the human body, is the primary factor contributing to the segment’s large market share.
- Furthermore, the increasing number of drug launches and product approvals for human monoclonal antibodies, enhanced efficacy, improved safety profiles, and the use of humanized animal models for the production of research & diagnostic monoclonal antibodies (MABs) contribute to this segment’s large market share.
By End User
- The Hospitals Segment to Dominate the Monoclonal Antibodies Market
- The hospitals segment is expected to account for the largest share of the monoclonal antibodies market.
- This segment’s large market share can be attributed to the rising number of patient visits to hospitals seeking various treatments, including monoclonal antibody therapy, the availability of dedicated facilities for the administration of monoclonal antibody drugs and access to advanced technological resources, and the proliferation of hospitals offering monoclonal antibody therapy.
- For instance, starting in February 2022, Northern Arizona Healthcare (U.S.) began offering monoclonal antibody treatment for COVID-19 patients at no cost at dedicated facilities in Flagstaff and Cottonwood.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 34.9% of the monoclonal antibodies market. North America's significant market share can be attributed to various factors, including the increasing prevalence of target diseases such as cancer and cardiovascular diseases, the increasing funding allocated for the development of monoclonal antibodies, the presence of key market players in the region, the rising number of clinical trials for monoclonal antibodies, and favorable reimbursement policies. For instance, in June 2024, the Federal Emergency Management Agency (U.S.), an agency of the U.S. Department of Homeland Security, allocated USD 50 million as reimbursement to the Commonwealth of Massachusetts for the cost of delivering monoclonal antibody treatments to the public during the COVID-19 pandemic. North America to Dominate the Market in 2025
Asia-Pacific
Fastest growthHowever, the market in Asia-Pacific is projected to register the highest growth rate of 13.4% during the forecast period. Countries in the region, including China, India, and South Korea, are expected to offer significant opportunities for market growth. The market growth in Asia-Pacific is driven by factors such as the expanding pharmaceutical and biotech industry, supportive government initiatives, the increasing number of clinical trials conducted in the region, and the rising demand for biologics to treat chronic and infectious diseases. Additionally, key players are ramping up production and receiving approvals for monoclonal antibody production in Asia Pacific countries, driven by the growing demand and usage in the region. For instance, in January 2025, AstraZeneca plc (U.K.) and Sanofi S.A. (France) received approval for Beyfortus (nirsevimab) in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants. Furthermore, in November 2024, Aragen Life Sciences (India) invested USD 30 million to establish a biologics manufacturing facility in India, focusing on the production of monoclonal antibodies, fusion proteins, and therapeutic proteins, thereby enhancing the company’s production capacity.
Competitive landscape
- March 2025
F. Hoffmann-La Roche AG (Switzerland) launched Vabysmo (faricimab), a bispecific monoclonal antibody, in India for the treatment of diabetic macular edema (DME) and neovascular or wet age-related macular degeneration (nAMD). With this launch, the company expanded its product portfolio in monoclonal antibodies for the ophthalmology therapeutic area.
- December 2024
KBI Biopharma, a JSR Life Sciences company (U.S.), launched SUREmAb, a MAB solution based on KBI’s SUREtechnology Platform designed for cost-efficient, safe, and optimized monoclonal antibody (mAb) manufacturing and development.
- August 2024
Regeneron Pharmaceuticals, Inc. (U.S.) signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA) as a part of Project NextGen. This agreement aims to support the clinical development, manufacturing, and regulatory licensure process for a next-generation COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection.
- June 2024
UCB (Belgium), a biopharmaceutical company, received U.S. FDA approval for RYSTIGGO (rozanolixizumab-noli) under Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients. The approved antibody is a humanized IgG4 monoclonal antibody for subcutaneous infusion.
- Novartis AG · Switzerland
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche AG · Switzerland
- AbbVie Inc. (U.S.)
- Amgen Inc. (U.S.)
- Bristol-Myers Squibb (U.S.)
- GSK plc (U.K.)
- Merck KGaA · Germany
- Eli Lilly and Company (U.S.)
- AstraZeneca plc (U.K.)
- Johnson & Johnson (U.S.)
- Takeda Pharmaceutical Company Limited · Japan
- Daiichi Sankyo Company · Japan
- Biogen (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
Frequently asked questions
The Monoclonal Antibodies Market focuses on therapeutic and diagnostic monoclonal antibodies, vital for treating diseases like cancer, autoimmune disorders, and infections, driven by advanced biopharmaceutical research.
Cite this report
Meticulous Research. (2024). Monoclonal Antibodies Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041246). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/monoclonal-antibodies-market-5929